GSK's Arexvy and Pfizer's shot Abrysvo, both protein-based vaccines, are also approved in Canada for adults aged 60 years and ...

Analysis of Pfizer's financial performance, acquisitions, and future prospects, highlighting key challenges and opportunities ...

AstraZeneca's China president has been detained by Chinese authorities amid investigation into illegal importation and ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

Pfizer Inc. (NYSE:PFE) is a global biopharmaceutical company that develops and markets medicines and vaccines across areas ...

Viatris is poised for appreciation with new product launches and a stronger balance sheet. Read why VTRS stock is a buy due ...

On Thursday, Pfizer Inc (PFE) stock saw a modest uptick, ending the day at $27.46 which represents a slight increase of $0.10 or 0.37% from the prior close of $27.36. The stock opened at $27.53 and ...

Health professionals recommend vaccines before traveling to celebrate the holidays with family. If you missed the early fall ...

The Dow Jones Industrial Average's shift away from value and income could open the door for other mega-cap growth stocks.

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

There are two other vaccines already available in Canada to protect seniors against severe illness caused by RSV: Arexvy, ...

With an array of new medicines and medical devices on display, global medical companies are looking to tap further into the ...